Rosuvastatin

Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: Reduce LDL-C in adults with primary hyperlipidemia. Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.

12.1 Mechanism of Action Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

Systemic exposure to Rosuvastatin reflects ~20% systemic bioavailability (Rosuvastatin) absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across rosuvastatin regimens, sustaining receptor engagement across a Terminal t½ estimated at 10–17 hrs depending on renal/hepatic reserve (Rosuvastatin) half-life window (peak plasma tmax within 3 to 5 hours (rosuvastatin) response profile).

Dosing protocols (20 mg/1 Tablet, Film Coated or 10 mg/1 Tablet, Coated or 10 mg/1 Tablet, Film Coated or 40 mg/1 Tablet or 5 mg/1 Tablet, Film Coated) balance efficacy (81.00% patient satisfaction across 6 logs) against nausea (12.4% of reports), headache (11% of reports), constipation (6.9% of reports), with strict avoidance in rosuvastatin tablets are contraindicated in the following conditions: acute liver failure or decompensated cirrhosis .; hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets.; hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets ..